Amrubicin therapy improves patients with refractory small-cell lung cancer: A single-arm confirmatory Chinese clinical study

作者：Zheng, Mengli; Zhou, Naikang^*; Ma, Lianjun; Jin, Wenbo

来源：Bangladesh Journal of Pharmacology, 2016, 11(3): 564-569.

DOI：10.3329/bjp.v11i3.23953

• ACTIVE METABOLITE AMRUBICINOL
• PREVIOUSLY UNTREATED PATIENTS
• PHASE-II
• ELDERLY-PATIENTS
• IN-VITRO
• CHEMOTHERAPY
• 9-AMINOANTHRACYCLINE
• CARBOPLATIN
• CISPLATIN
• GENE

Our objective was to evaluate an open-label, multicenter, single-arm study to appraise whether amrubicin therapy improves patients with refractory smallcell lung cancer in Chinese clinical study. Patients (n=95) with refractory small-cell lung cancer received 3 consecutive days amrubicin therapy for 21 days. Overall response rate of response to amrubicin was 39%. Anemia, febrile neutropenia, thrombocytopenia, hyperglycemia, hyponatremia, infection, elevated serum transaminases levels were appeared, but the incidences of adverse events were very few. Our results suggest amrubicin therapy can improve patients with refractory small-cell lung cancer and may be an effective and safe treatment option.

• 出版日期2016
• 单位中国人民解放军第三〇九医院